Peptide merchant accounts UK
UK peptide sellers need a specialist high-risk acquirer panel because mainstream processors decline the category outright. Stripe, PayPal, SumUp, Square, Zettle, Worldpay and Barclaycard classify research peptides alongside unlicensed medicines and research chemicals, and either reject at onboarding or terminate and hold funds once the catalogue is reviewed. Specialist research-chemical and nutraceutical acquirers underwrite peptides instead, on a case-by-case basis, at higher blended rates with a substantial rolling reserve against chargebacks and regulatory risk. Expect strict scrutiny of your labelling, disclaimers and claims at compliance.
Legal status (UK)
Sold lawfully in the UK only as research chemicals or laboratory reagents, labelled not for human consumption. Marketing peptides for human use, dosing or injection makes them unlicensed medicines and brings them under MHRA enforcement. The legal position turns entirely on how the product is presented.
Best way to take Peptide payments (UK)
Our pick
MerchantHQ, specialist Peptide broker and account team
Mainstream UK acquirers (SumUp, Square, Zettle, Dojo, Worldpay, Barclaycard) decline Peptide at onboarding or terminate after launch. We hold a specialist panel of UK high-risk acquirers that underwrite it. As a broker we match you to the right one for your licence, volume and processing history, then stay on as your named UK account team for the life of the agreement.
The acquirer pays our commission on signup, so it costs you nothing on top, and we never sell your details on. We disclose the risk classification upfront so the right underwriter is approached from the start.
Get matched to a Peptide acquirerHigh-risk merchants are the most exposed to chargebacks, frozen funds and MATCH/TMF listings, and that is exactly what your MerchantHQ account team handles, for the life of the agreement.
How Peptide placements work
Peptide routes to specialist regulated-vertical acquirers matched per application rather than a published list. The right underwriter depends on your licence, volume and sub-category, so we approach it individually. We hold the relationships and disclose your risk classification upfront so the right acquirer is contacted from the start.
Typical pricing
- Rate
- 3.5% to 6.0% blended
- Settlement reserve
- 10% to 20% rolling reserve common
Watch outs
- Product pages must label peptides as research chemicals not for human consumption; any human-use, dosing or injection guidance reclassifies them as unlicensed medicines under MHRA rules and triggers acquirer termination.
- No medical, therapeutic, performance or anti-ageing claims anywhere on site, in metadata or in ads.
- Mainstream processors (Stripe, PayPal, SumUp) routinely freeze peptide accounts post-onboarding once the category is identified; have a compliant specialist account in place from day one.
- Age-gating, COA / batch documentation and clear returns terms are reviewed at underwriting.
- GLP-1 peptides (semaglutide, tirzepatide) are prescription-only medicines, not research chemicals; selling them without a pharmacy registration is a separate and more serious offence.
Director, MerchantHQ
Oliver leads MerchantHQ's terminal testing and acquirer comparison. With a background in UK commercial finance and merchant payments, he oversees terminal reviews, switching guidance and high-risk vertical mapping.
Last reviewed: 3 June 2026